<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160159</url>
  </required_header>
  <id_info>
    <org_study_id>P071012</org_study_id>
    <secondary_id>IDRCB 2008-A01635-50</secondary_id>
    <nct_id>NCT01160159</nct_id>
  </id_info>
  <brief_title>Arterial Microcirculation, Macrocirculation and Thrombophilias</brief_title>
  <acronym>MICMAC</acronym>
  <official_title>Arterial Microcirculation, Macrocirculation and Thrombophilias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: To analyse the arterial state of women with thrombophilia by techniques studying&#xD;
      micro and arterial macrocirculation because of a reported and still discussed increase risk&#xD;
      in cardio-vascular events in these women.&#xD;
&#xD;
      Primary objective: To measure endothelium dependent vasodilatation (VDE) in controls and in&#xD;
      women with thrombophilia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are several papers reporting an increase in the risk of arterial diseases in women with&#xD;
      thrombophilia. However these reports remain controversial. In order to gain insight on that&#xD;
      issue we propose to study the micro and macrocirculation in women with an history of venous&#xD;
      thrombosis or thrombophilia and in controls matched by age.&#xD;
&#xD;
      Design: It is a prospective open transversal trial.&#xD;
&#xD;
      Management of the study: Two groups of 80 women will be compared: healthy volunteers and&#xD;
      women with thrombophilia. Following an inclusion consultation where the informed consent will&#xD;
      be obtained and inclusion criteria checked, an appointment for the arterial explorations will&#xD;
      be given. These explorations will be measurement of endothelium dependent vasodilatation&#xD;
      (EDV), capillar density, arterial fitness and compliance and retinogram. There is no&#xD;
      follow-up visit.Benefits and risks: the measurement will characterize the arterial state of&#xD;
      patients with thrombophilia included in the study.There is no risk in performing these&#xD;
      techniques.&#xD;
&#xD;
      Principal criteria: measurement of EDV.&#xD;
&#xD;
      Secondary criteria: capillar density, arterial compliance and stiffness and retinogram.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vasodilatation endothelium-dependent (VDE)</measure>
    <time_frame>at 2 months max after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Capillary density</measure>
    <time_frame>at 2 months max after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stiffness and arterial compliance</measure>
    <time_frame>at 2 months max after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of venous and arterial microcirculation using images acquired by retinogram and a specific software</measure>
    <time_frame>at 2 month</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Thrombophilia</condition>
  <arm_group>
    <arm_group_label>Thrombophilia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tests</intervention_name>
    <description>Arterial parameters</description>
    <arm_group_label>Thrombophilia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Healthy volunteers</intervention_name>
    <description>Arterial parameters and blood test</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Two groups of 80 women will be compared: healthy volunteers and women with thrombophilia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy volunteers&#xD;
&#xD;
               -  18-45 years old women of child bearing age&#xD;
&#xD;
               -  Without any hormonal contraception nor any hormone treatment since at least 3&#xD;
                  months&#xD;
&#xD;
               -  Without any arterial risk factors (HTA, diabetes, dyslipemia, obesity, including&#xD;
                  smoking&gt; 5 cigaret )&#xD;
&#xD;
               -  Patient who have signed an inform consent&#xD;
&#xD;
               -  With no thrombophilia : normal sample for factor V and II mutations&#xD;
&#xD;
               -  Willing to participate to the study&#xD;
&#xD;
               -  Adherent to health insurance&#xD;
&#xD;
               -  Previous Clinical examination&#xD;
&#xD;
          -  women with thrombophilia&#xD;
&#xD;
               -  18-45 years old women of child bearing age&#xD;
&#xD;
               -  Without any hormonal contraception nor any hormone treatment since at least 3&#xD;
                  months&#xD;
&#xD;
               -  Without any arterial risk factors (HTA, diabetes, dyslipemia, obesity, including&#xD;
                  smoking&gt; 5 cigaret )&#xD;
&#xD;
               -  Patient who have signed an inform consent&#xD;
&#xD;
               -  With thrombophilia : normal sample for factor V and II mutations&#xD;
&#xD;
               -  Willing to participate to the study&#xD;
&#xD;
               -  Adherent to health insurance&#xD;
&#xD;
               -  Previous Clinical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women under hormonal contraception or who have stopped it less than 3 months ago&#xD;
&#xD;
          -  Women under anticoagulant&#xD;
&#xD;
          -  Arterial risk factor : HTA, diabetes, dyslipemia, obesity(BMI&gt;30), including smoking&gt;&#xD;
             5 cigarets ), metabolic syndrome, antiphospholipids/anticoagulant antibody, SLE&#xD;
&#xD;
          -  History of coronaropathy or of stroke&#xD;
&#xD;
          -  Pregnant women or willing to conceive&#xD;
&#xD;
          -  Severe liver disease&#xD;
&#xD;
          -  Women of less than 18y or older than 45y&#xD;
&#xD;
          -  Severe liver diseases&#xD;
&#xD;
          -  Patient not willing to sign up the inform consent&#xD;
&#xD;
          -  Patient refusal to participate&#xD;
&#xD;
          -  Endometrial cancer&#xD;
&#xD;
          -  Unexplored bleeding&#xD;
&#xD;
          -  Women not willing to participate or included in another trial&#xD;
&#xD;
          -  Woman with another thrombophilic disorder (ATIII, protein C, S, history of VTE without&#xD;
             any biological thrombophilic disorder.&#xD;
&#xD;
          -  Women with at least one of the following treatment and who cannot stop it 48h before&#xD;
             the arterial investigations.&#xD;
&#xD;
          -  Gynergen caffeine&#xD;
&#xD;
          -  NOCERTONE® oxetorone&#xD;
&#xD;
          -  SIBÉLIUM®flunarizine&#xD;
&#xD;
          -  VIDORA®indoramine&#xD;
&#xD;
          -  SANMIGRAN® 0,50 mg pizotifen&#xD;
&#xD;
          -  woman under propranolol AVLOCARDYL® 40 mg *AVLOCARDYL® LP 160 mg&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne GOMPEL, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève PLU-BUREAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne GOMPEL, MD-PhD</last_name>
    <phone>33(1)42-34-80-99</phone>
    <email>anne.gompel@htd.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Hotel Dieu - Consultation Gynécologie et d'Hémostase</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne GOMPEL, MD,PhD</last_name>
      <phone>33(1) 42-34-80-99</phone>
      <email>anne.gompel@htd.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Geneviève PLU-BUREAU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Myriem CARRIER</name_title>
    <organization>Department of clinical research and development</organization>
  </responsible_party>
  <keyword>Venous thrombosis</keyword>
  <keyword>Women</keyword>
  <keyword>Vasodilatation endothelium-dependent</keyword>
  <keyword>IMT</keyword>
  <keyword>Arterial stiffness</keyword>
  <keyword>Arterial compliance</keyword>
  <keyword>Capillary density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

